Phase 2 Thyroid Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People with a life expectancy of at least 12 weeks
• People who have been confirmed through laboratory testing to have locally advanced or metastatic differentiated thyroid cancer (DTC) — including papillary, follicular, Hürthle cell, or poorly differentiated thyroid cancer — that cannot be removed by surgery or treated with radiotherapy
• People who have at least one tumour that can be measured on imaging scans, according to standard criteria (called RECIST 1.1)
• People whose thyroid cancer no longer responds to radioiodine (RAI) treatment, based on specific criteria such as: tumour(s) that did not take up radioiodine during scanning or treatment; tumour(s) that continued to grow within 14 months of radioiodine therapy despite showing uptake at the time; or a total lifetime dose of radioiodine above a certain level, with the last dose given at least 6 months before joining the study
• People whose cancer did not respond to, or who could not tolerate, at least one prior treatment with a type of drug called a tyrosine kinase inhibitor (TKI); if prior treatment included a specific type of TKI targeting blood vessel growth (VEGFR-TKI), no more than two of these are allowed
• People who are able to provide a stored tumour tissue sample or a previous test report for a particular protein marker (MET); if no stored sample is available, a fresh tissue biopsy (taken by needle or core needle, not fine needle) is an option — people who cannot provide tissue or test reports may still be considered if the trial doctor believes ST-1898 could offer potential benefit (confirm with trial site)
• People with a general health and activity level rated as 0 or 1 on a standard scale (meaning fully active or able to carry out light work)
• People who are well-managed on thyroid hormone suppression therapy, with thyroid-stimulating hormone (TSH) levels below a certain threshold
• People whose blood counts, liver, kidneys, blood clotting, heart function, and urine protein levels all fall within the ranges required by the trial (confirm specific values with trial site)
• People who are willing and able to read and sign a consent form agreeing to take part
• People who are willing to use effective contraception throughout the study and for at least 3 months after the last dose; women who could become pregnant must have a negative pregnancy blood test within 7 days before starting treatment

Who may not be able to join:

• People with a type of thyroid cancer other than differentiated thyroid cancer, such as anaplastic thyroid carcinoma or medullary thyroid carcinoma
• People with a known allergy or sensitivity to any ingredient in the study drug (ST-1898)
• People who have received any cancer treatment within 4 weeks (or within 5 half-lives of that treatment, whichever is shorter) before starting the study drug
• People who have had major surgery, an open biopsy, or a significant physical injury within 4 weeks before starting the study drug
• People with serious wounds, ulcers, or bone fractures that have not healed
• People who have had a severe bleeding event (grade 3 or above) in the 6 months before starting the study, or who currently have moderate-to-severe bleeding, or who have a high risk of bleeding (such as blood clotting problems, bleeding into the airways, active stomach ulcers, or enlarged veins in the oesophagus)
• People who have coughed up blood, or more than about half a teaspoon (2.5 mL) of blood per day, within 2 months before starting the study
• People currently taking antiplatelet medicines (low-dose aspirin of 100 mg per day or less is allowed)
• People with current or previous severe eye disease (retinopathy) that the trial doctor or a specialist considers unsuitable for participation
• People with significant heart problems, including: serious irregular heartbeat or heart conduction problems requiring treatment; an abnormally prolonged heart electrical interval (QTcF above 450 ms for men or 480 ms for women); recent heart attack, stroke, blood clots in deep veins or lungs, arterial clots, heart failure, or aortic dissection; heart failure rated as class II or above on a standard scale; or blood pressure consistently above 140/90 mmHg that cannot be controlled
• People with brain metastases (cancer that has spread to the brain) that have not been adequately treated or have not been stable for at least 4 weeks before starting the study, or who still have neurological symptoms, or who are on a changing dose of steroid medication
• People with lung inflammation (interstitial lung disease or radiation pneumonia) that requires steroid treatment
• People who have had another cancer in the past 5 years, with the exception of certain cancers that have been cured (non-melanoma skin cancer, breast or cervical cancer in situ, and non-muscle-invasive bladder cancer)
• People who have been taking strong medicines that significantly affect a liver enzyme called CYP3A4 within 2 weeks before starting the study drug (confirm specific medicines with trial site)
• People who have previously been treated with a type of drug called a BRAF inhibitor
• People who have not recovered from side effects of previous cancer treatments to a mild or acceptable level (with some exceptions such as mild nerve tingling or hair loss)
• People who test positive for HIV or syphilis antibodies; people with active hepatitis B (above a certain viral level); people who test positive for both hepatitis C antibody and hepatitis C virus RNA; or people with other active liver infections or significant liver scarring (cirrhosis)
• People with an active bacterial, viral, or fungal infection currently requiring treatment
• People who are pregnant or breastfeeding
• People with alcohol or drug dependence
• People with significant neurological or psychiatric conditions, or who are unlikely to be able to follow the study requirements
• People who are unable to swallow tablets, or who have conditions that affect the absorption of oral medicines, such as difficulty swallowing or bowel obstruction
• People with uncontrolled fluid build-up around the lungs, heart, or abdomen that requires frequent draining or medical treatment
• People with any other serious health condition or circumstance that the trial doctor believes would make participation unsafe or affect the reliability of the trial results

Important: Always verify eligibility with the trial site directly before applying.